AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea · Delayed Price · Currency is KRW 4,495.00
-175.00 (-3.75%)
Nov 13, 2026, 3:30 PM KST
AptaBio Therapeutics Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Revenue Revenue Growth | 4,753 | 3,698 | 3,361 | 323.87 | 48.35 |
Revenue Growth | 52.91% | 10.03% | 937.76% | 569.80% | - |
Gross Profit Gross Profit Growth | 2,244 | 1,289 | 273.69 | 61.06 | 37.21 |
Operating Income Operating Income Growth | -18,752 | -15,536 | -20,715 | -16,904 | -9,507 |
Net Income Net Income Growth | -14,869 | -16,346 | -29,378 | -11,866 | -10,565 |
Earnings Per Share EPS Growth | -540.42 | -607.49 | -1247.79 | -532.16 | -474.00 |
EPS Growth | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
New Business Division - Product Sales (ODM) New Business Division - Product Sales (ODM) Growth | 964.08 | 1,434 | 1,682 | 209.82 | - |
New business division - Product Sales (General) New business division - Product Sales (General) Growth | 5.14 | 48.73 | 1,563 | 61.74 | 48.35 |
Objectivo Business Division - Product Sales (General) Objectivo Business Division - Product Sales (General) Growth | 4,281 | 2,171 | - | - | - |
Research and Development Department - Reagent Sales Research and Development Department - Reagent Sales Growth | 49.29 | 44.29 | 116.39 | 52.31 | - |
Total Total Growth | 5,299 | 3,698 | 3,361 | 323.87 | 48.35 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Investments Cash & Investments Growth | 15,725 | 17,190 | 31,515 | 52,885 | 17,015 |
Total Debt Total Debt Growth | 4,913 | 4,422 | 7,521 | 13,934 | 366.03 |
Net Cash (Debt) Net Cash Growth | 10,812 | 12,768 | 23,994 | 38,951 | 16,649 |
Net Cash Growth | -23.18% | -46.79% | -38.40% | 133.95% | - |
Net Cash Per Share Net Cash Per Share Growth | 392.96 | 474.51 | 1019.11 | 1746.78 | 746.98 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -17,373 | -15,276 | -12,160 | -14,095 | -6,833 |
Capital Expenditures CapEx Growth | -30.87 | -58.67 | -240.16 | -1,345 | -1,041 |
Free Cash Flow Free Cash Flow Growth | -17,404 | -15,335 | -12,400 | -15,440 | -7,874 |
Free Cash Flow Growth | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Gross Margin | 47.21% | 34.84% | 8.14% | 18.86% | 76.95% |
Operating Margin | -394.53% | -420.14% | -616.35% | -5219.25% | -19661.23% |
Pretax Margin | -291.66% | -414.83% | -827.22% | -4536.36% | -21849.26% |
Profit Margin | -312.83% | -442.04% | -874.09% | -3663.98% | -21849.26% |
FCF Margin | -366.15% | -414.69% | -368.94% | -4767.39% | -16284.04% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Forward PE | - | 78.10 | 78.10 | 78.10 | 78.10 |
PS Ratio | 26.57 | 67.97 | 50.95 | 623.11 | 4911.46 |